In last trading session, Humacyte Inc (NASDAQ:HUMA) saw 3.74 million shares changing hands with its beta currently measuring 1.45. Company’s recent per share price level of $5.81 trading at $0.11 or 1.93% at ring of the bell on the day assigns it a market valuation of $727.47M. That closing price of HUMA’s stock is at a discount of -71.6% from its 52-week high price of $9.97 and is indicating a premium of 66.27% from its 52-week low price of $1.96. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.92 million shares which gives us an average trading volume of 2.92 million if we extend that period to 3-months.
For Humacyte Inc (HUMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.25 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Humacyte Inc (NASDAQ:HUMA) trade information
Upright in the green during last session for gaining 1.93%, in the last five days HUMA remained trading in the green while hitting it’s week-highest on Wednesday, 10/16/24 when the stock touched $5.81 price level, adding 7.19% to its value on the day. Humacyte Inc’s shares saw a change of 104.58% in year-to-date performance and have moved 7.89% in past 5-day. Humacyte Inc (NASDAQ:HUMA) showed a performance of 11.09% in past 30-days. Number of shares sold short was 16.03 million shares which calculate 6.28 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4.5 to the stock, which implies a fall of -29.11% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would jump 31.15% in reaching the projected high whereas dropping to the targeted low would mean a gain of 31.15% for stock’s current value.
Humacyte Inc (HUMA) estimates and forecasts
Statistics highlight that Humacyte Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 86.22% of value to its shares in past 6 months, showing an annual growth rate of -1.87% while that of industry is 17.40. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
And 5 analysts are in estimates of company making revenue of 420k in the next quarter.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders are in possession of 27.91% of company’s total shares while institution are holding 25.50 percent of that, with stock having share float percentage of 35.37%. Investors also watch the number of corporate investors in a company very closely, which is 25.50% institutions for Humacyte Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HUMA for having 7.14 million shares of worth $34.27 million. And as of 2024-06-30, it was holding 6.5961 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.73 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.3693 of outstanding shares, having a total worth of $22.7 million.
